

TSCA HEALTH & SAFETY STUDY COVER SHEET

MR 280105

TSCA CBI STATUS: NONE

8EHQ-1004-15757

1.0 SUBMISSION TYPE <input type="checkbox"/> 8(d) <input checked="" type="checkbox"/> 8(e) <input type="checkbox"/> FYI <input type="checkbox"/> 4 <input type="checkbox"/> OTHER: Specify _____ XX- Initial Submission - Follow-up Submission <input type="checkbox"/> Final Report Submission Previous EPA Submission Number or Title if update or follow-up: _____ Docket Number, if any: # _____ <input type="checkbox"/> continuation sheet attached		
2.1 SUMMARY/ABSTRACT ATTACHED (may be required for 8(e): optional for §4, 8(d) & FYI) X- YES <input type="checkbox"/> NO	2.2 SUBMITTER TRACKING NUMBER OR INTERNAL ID 7106 4575 1292 0338 1026 L-04-2-1	2.3 FOR EPA USE ONLY
3.0 CHEMICAL/TEST SUBSTANCE IDENTITY CAS#: 3173-53-3 <u>Reported Chemical Name (specify nomenclature if other than CAS name):</u> Cyclohexylisocyanate Purity ____% X- Single Ingredient <input type="checkbox"/> Commercial/Tech Grade <input type="checkbox"/> Mixture <u>Trade Name</u> Cyclohexylisocyanate <u>Common Name:</u> _____ <u>CAS Number</u> _____ <u>NAME</u> _____ <u>% WEIGHT</u> _____ Other chemical(s) present in tested mixture _____ <input type="checkbox"/> continuation sheet attached		
4.0 REPORT/STUDY TITLE In Vitro chromosome Aberration Test with Chinese Hamster V79 Cells – T5073221 <input type="checkbox"/> continuation sheet attached		
5.1 STUDY/TSCATS INDEXING TERMS [CHECK ONE] HEALTH EFFECTS (HE): <u>X</u> ENVIRONMENTAL EFFECTS (EE): _____ ENVIRONMENTAL FATE (EF): _____		
5.2 STUDY/TSCATS INDEXING TERMS (see instructions for 4 digit codes) STUDY SUBJECT ROUTE OF VEHICLE OF TYPE: Vitro ORGANISM (HE, EE) <u>HAMS</u> EXPOSURE (HE only): _____ EXPOSURE (HE only) _____ Other: _____ Other: _____ Other: _____		
6.0 REPORT/STUDY INFORMATION <input type="checkbox"/> Study is GLP Laboratory <u>Bayer Healthcare AG Toxicology</u> Report/Study Date: 10/8/2004 Source of Data/Study Sponsor (if different than submitter) <u>Lanxess Corporation</u> Number of pages - _____ <input type="checkbox"/> continuation sheet attached		
7.0 SUBMITTER INFORMATION Susan VanVolkenburg Manager, Product Safety & Regulatory Affairs Lanxess Corporation 100 Bayer Road Pittsburgh, PA 15205 412-777-4185 Technical Contact: <u>SAME AS ABOVE</u> Phone: () _____ <input type="checkbox"/> continuation sheet attached		
8.0 ADDITIONAL/OPTIONAL STUDY COMMENTS This compound is a commercial product. <input type="checkbox"/> continuation sheet attached		

Submitter Signature: Susan VanVolkenburg Date: 10/8/2004

9.0 CONTINUATION SHEET

Submitter Tracking Number/Internal ID

7106 4575 1292 0338 1026

L-04-2-1

Continuation of 2.1

Reporting is based on the following summary results.

SUMMARY:

The clastogenic potential of Cyclohexylisocyanat was evaluated in a chromosome aberration test in vitro. Initially Chinese hamster V79 cells were exposed in the absence of S9 mix for 4 hours to concentrations of 1, 2, 4, 6, and 8 µg/ml of Cyclohexylisocyanat. Cultures of all concentrations were harvested 18 hours after the beginning of the treatment. In addition, cells treated with 4, 6, and 8 µg/ml were harvested 30 hours after the beginning of the treatment. In the presence of S9 mix cells were exposed for to concentrations of 4, 8, 18, 22, and 26 µg/ml of Cyclohexylisocyanat. Cultures of all concentrations were harvested 18 hours after the beginning of the treatment. In addition, cells treated with 18, 22 and 26 µg/ml were harvested 30 hours after the beginning of the treatment. Based on their cytotoxicity concentrations were selected for reading of metaphases.

Without S9 mix cytotoxic effects were observed at 2 µg/ml and above. With S9 mix cytotoxic effects were observed at 4 µg/ml and above. Precipitation in the medium was not observed.


Therefore, concentrations of 1, 2 and 4 µg/ml Cyclohexylisocyanat were chosen for reading in the absence of S9 mix. In the presence of S9 mix 4, 8 and 18 µg/ml of Cyclohexylisocyanat were employed. All of these cultures harvested 18 hours after the beginning of the treatment were included. In addition, cultures treated in the absence of S9 mix with 4 µg/ml and harvested 30 hours after the beginning of the treatment were used. The same was true for cultures treated in the presence of S9 mix with 18 µg/ml.

In the absence of S9 mix cultures treated with Cyclohexylisocyanat showed at 4 µg/ml statistically significant increases for the numbers of aberrant metaphases which were of questionable biological relevance. However, in the presence of S9 mix cultures treated with Cyclohexylisocyanat showed biologically relevant and statistically significant increased numbers of aberrant metaphases at 18 µg/ml.

The positive controls mitomycin C and cyclophosphamide induced clastogenic effects and demonstrated the sensitivity of the test system and the activity of the used S9 mix.


Based on this test, Cyclohexylisocyanat is considered to be clastogenic for mammalian cells in vitro, at least with S9 mix.

NO STICKER



TO THE RIGHT OF RETURN ADDRESS
FOLD AT DOTTED LINE

CERTIFIED MAIL



7106 4575 1292 0338 1026

RETURN RECEIPT REQUESTED